Barrack Rodos Files Suit on Behalf of Purchasers of PE Corporation Celera Genomics Group Stock in February 29, 2000 Secondary Offering.

Business Editors/Legal Writers

PHILADELPHIA--(BUSINESS WIRE)--June 1, 2000

Counsel for Class Plaintiff, Barrack, Rodos & Bacine, today issued the following:

A class action has been commenced in the United States District Court for the District of Connecticut on behalf of all persons who purchased the stock of PE Corporation Celera Genomics Group (NYSE: CRA) ("Celera" or the "Company") in a secondary offering (the "Secondary Offering") of Celera common stock conducted by PE Corporation on February 29, 2000.

To sign up online: http://www.barrack.com/NewCases/NewCases.htm

The plaintiff seeks to recover damages on behalf of class members and is represented by the law firm of Barrack, Rodos & Bacine, which has extensive experience in prosecuting investor class actions. Barrack, Rodos & Bacine has prosecuted securities, antitrust and consumer class actions for over 20 years. The firm has offices in Philadelphia, San Diego, New York, Boston and New Jersey and has been designated lead counsel by federal and state courts across the country in large, complex cases. For more information about Barrack, Rodos & Bacine, please visit their website at www.barrack.com.

If you are a member of the Class described above, you may, no later than June 19, 2000, move the Court to serve as lead plaintiff of the Class, if you so choose. In order to serve as lead plaintiff, however, you must meet certain legal requirements. If you wish to discuss this action or have any questions concerning this case or your rights or interests, please contact Maxine S. Goldman, Shareholder Relations Manager, at Barrack, Rodos & Bacine, 3300 Two Commerce Square, 2001 Market Street, Philadelphia, PA 19103, at 800-417-7305 or 215-963-0600, fax number 888-417-7306 or 215-963-0838 or by e-mail at [e-mail].